Floatz logo

Palbociclib

Her2-Receptor Negative Breast Cancer

Helwan UniversitySmall moleculePhase 2Active
BBB
75/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
63/ 100
Competitive Position
95/ 100

Competitive context

185 Active assets in the Her2-Receptor Negative Breast Cancer cohort.

Asset / SponsorPhaseRating
EXEMESTANE
National Cancer Institute (NCI)
Phase 4BBB
Pembrolizumab
UNC Lineberger Comprehensive Cancer Center
Phase 2BBB
Atezolizumab
TransThera Sciences (Nanjing), Inc.
Phase 2BB
Docetaxel
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 2/3BB
Capecitabine
Kristina A. Fanucci
Phase 4BB

View all 50 →

Same molecule, other indications

Palbociclib is also rated in:

hormone receptor-positive breast cancerActive
BBB
Indicative · Phase 3
73 / 100
View asset →
breast cancerActive
BB
Indicative · Phase 4
71 / 100
View asset →
ovarian carcinomaActive
BB
Indicative · Phase 4
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →